|
Adverse event
|
Cisplatin + gemcitabine + axitinib (n = 38)
|
|---|
|
All grades
|
Grade ≥3
|
|---|
|
No.
|
%
|
No.
|
%
|
|---|
|
Nausea
|
16
|
42.1
| | |
|
Anaemia
|
12
|
31.6
|
3
|
7.9
|
|
Vomiting
|
11
|
28.9
|
2
|
5.3
|
|
Hypertension
|
10
|
26.3
|
5
|
13.2
|
|
Neutropaenia
|
9
|
23.7
|
5
|
13.2
|
|
Weight loss
|
9
|
23.7
|
0
|
0
|
|
Appetite loss
|
8
|
21.1
|
0
|
0
|
|
Fatigue
|
7
|
18.4
|
3
|
7.9
|
|
Asthenia
|
6
|
15.8
|
0
|
0
|
|
Leukopaenia
|
5
|
13.2
|
2
|
5.3
|
|
Diarrhoea
|
5
|
13.2
|
0
|
0
|
|
Reduced creatinine clearance
|
5
|
13.2
|
0
|
0
|
|
Alopecia
|
5
|
13.2
|
0
|
0
|
|
Thrombocytopaenia
|
4
|
10.5
|
0
|
0
|
|
Chest pain
|
4
|
10.5
|
0
|
0
|
|
Toxic nephropathy
|
4
|
10.5
|
0
|
0
|
|
Cough
|
4
|
10.5
|
0
|
0
|
|
Dyspnoea
|
4
|
10.5
|
0
|
0
|
|
Rash
|
4
|
10.5
|
0
|
0
|
|
Pulmonary cavitation
|
3
|
7.9
|
1
|
2.6
|
|
Haemoptysis
|
3
|
7.9
|
1
|
2.6
|
- ITT = intent-to-treat.
- *Study period comprised the treatment period plus 28-day follow-up period after the last dose of study drug.
